Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Chief Financial Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,220 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,220 · Balance 37,220 F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-20 · Other · Disposed 570,719 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 570,719 |
Reported balance
After 2026-04-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-20 · Other · Acquired 570,719 · Balance 570,719 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date August 22, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 143,242 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Sale · Disposed 2,961 · Balance 143,242 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · derivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 600,000 shares, of which 169,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $198.09 | $19,809.00 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $194.92 | $38,984.00 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,457 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 794 | $193.40 | $153,559.68 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,657 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $193.07 to $193.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,706 | $192.46 | $713,241.19 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,451 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.06 to $192.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,700 | $191.77 | $517,783.32 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,157 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.08 to $192.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,900 | $190.63 | $362,191.11 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,857 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.10 to $191.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $189.57 | $113,743.08 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,757 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.12 to $189.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-030397 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · derivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 600,000 shares, of which 159,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,800 | $185.76 | $334,360.98 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $185.62 to $186.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,795 | $185.02 | $702,152.04 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,157 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $184.62 to $185.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,205 | $184.12 | $590,095.63 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,952 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $183.62 to $184.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $183.19 | $128,230.97 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,157 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $182.61 to $183.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $181.83 | $36,365.00 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,857 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $181.56 to $182.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $180.02 | $54,006.99 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,057 F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $179.97 to $180.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-024709 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 22,338 | $0.00 Strike: $177.76 | $0.00 |
DisclosureSEC source: 0001209191-21-036102 · doc4.xml · derivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,338 Underlying: Class A Common Stock · 22,338 shares Expires 2031-03-19 F5 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036102 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,292 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: The number of shares beneficially owned following the reported transaction is as of March 19, 2021. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,583 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · derivative · entry 16 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,417 Underlying: Class A Common Stock · 9,583 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: This option, originally for 20,000 shares, of which 9,583 shares have been exercised, vested as to one forty-eighth of the shares on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,583 | $11.48 | $110,012.84 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 14 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · derivative · entry 15 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F14 · derivative.exercise_date: This option, originally for 600,000 shares, of which 149,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $154.82 | $15,482.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 13 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,774 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $154.14 | $46,241.01 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 12 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F13 · price: This transaction was executed in multiple trades at prices ranging from $153.58 to $154.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $152.08 | $60,833.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 11 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,174 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F12 · price: This transaction was executed in multiple trades at prices ranging from $151.96 to $152.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $151.22 | $120,977.04 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 10 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,574 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · price: This transaction was executed in multiple trades at prices ranging from $150.85 to $151.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $150.22 | $180,261.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,374 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $149.82 to $150.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $149.43 | $164,371.02 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,574 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $148.82 to $149.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $148.08 | $29,616.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,674 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $147.76 to $148.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,476 | $146.88 | $216,792.52 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $146.36 to $147.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,902 | $145.90 | $277,501.42 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,350 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $145.36 to $146.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $145.03 | $159,528.05 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,252 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $144.35 to $145.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $142.49 | $56,994.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,352 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $142.07 to $142.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,022 | $141.25 | $144,357.40 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,752 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $140.87 to $141.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-019646 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · derivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 600,000 shares, of which 139,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $178.49 | $89,247.00 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,774 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $178.11 to $178.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 910 | $177.50 | $161,525.18 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,274 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $177.03 to $177.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,777 | $176.51 | $490,170.77 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,184 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $176.02 to $177.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,213 | $175.53 | $915,026.94 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,961 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $175.00 to $175.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $174.18 | $104,509.02 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,174 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.50 to $174.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-007560 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · derivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 600,000 shares, of which 129,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $141.91 | $28,382.00 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,774 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.61 to $142.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,764 | $140.78 | $248,330.80 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,974 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.48 to $141.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,036 | $139.91 | $844,525.13 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,738 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.48 to $140.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $139.08 | $278,152.20 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,774 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.47 to $139.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-002193 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 19,841 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065241 · doc4.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,159 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, originally for 600,000 shares, of which 119,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 23:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 19,841 | $5.04 | $99,998.64 |
DisclosureSEC source: 0001209191-20-065241 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.